ESC Premium Access

Risk prediction in patients with venoarterial extracorporeal membrane oxygenation for cardiopulmonary support: insights from a German registry

Congress Session

About the speaker

Assistant Professor Peter Moritz Becher

University Heart and Vascular Center Hamburg, Hamburg (Germany)
0 follower

9 more presentations in this session

Long-term survival after early vs. late initiation of percutaneous mechanical support in infarct-related cardiogenic shock

Speaker: Doctor T. Loehn (Dresden, DE)

Thumbnail

Impact of extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) for cardiac arrest

Speaker: Mr N. Kuroki (Tokyo, JP)

Thumbnail

Systematic review of serum lactate as prognosticator in cardiogenic shock or arrest on ECMO

Speaker: Associate Professor G. Klappacher (Vienna, AT)

Thumbnail

Prognostic relevance of serum lactate clearance in critically ill patients admitted to ICU

Speaker: Doctor M. Masyuk (Duesseldorf, DE)

Thumbnail

Contemporary and real-life picture of cardiogenic shock in France: a descriptive analysis of the FRENSHOCK multicenter prospective registry

Speaker: Doctor C. Delmas (Toulouse, FR)

Thumbnail

Access the full session

Cardiogenic shock following myocardial infarction: beyond the mechanics

Speakers: Assistant Professor P. Becher, Doctor T. Loehn, Mr N. Kuroki, Associate Professor G. Klappacher, Doctor M. Masyuk...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Related content

Open Access

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

27 August 2021

ESC Premium Access

Effects of Sacubitril/valsartan compared with ramipril on coronary events after myocardial infarction - Results from the PARADISE-MI Trial

27 August 2021

ESC Premium Access

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

27 August 2021

This platform is supported by

logo Novo Nordisk